NCT05888493 2026-04-17
LEDA
Novartis
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT03269669 2026-04-13
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04542824 2026-04-08
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-04-08
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT06097364 2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT05371093 2025-10-15
ZUMA-22
Gilead Sciences
Phase 3 Active not recruiting
NCT02889523 2024-10-09
Epi-RCHOP
The Lymphoma Academic Research Organisation
Phase 1/2 Active not recruiting